FLT3 and acute myeloid leukemia: In addition, FLT3 N676K in the TKD domain has been shown to confer resistance to midostaurin—a well-known medicine used in frontline treatment in FLT3-mutated AML [90]—and the K429E mutation is associated with resistance to crenolanib [91].